Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib Plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women With ErbB2- (HER2/Neu-) Overexpressing Invasive Breast Cancer
收藏DataCite Commons2026-02-09 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012283/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study will examine safety and efficacy of Lapatinib in combination with a standard neoadjuvant chemotherapy including 5FU, Epirubicin, Cyclophosphamide and Paclitaxel. Tumor tissue will be obtained at 3 timepoints (optional 4th) to evaluate tumor response to treatment.
提供机构：
Vivli
创建时间：
2025-12-16
